How to order

DefenCath is available with participating health plans

DefenCath is available to order through Cardinal Health^™ Specialty Pharmaceutical Distribution. Please download the Product Ordering Sheet for information on how to order DefenCath.

Product Information

National Drug Code (NDC)	Carton — 10 vial pack — 10 digit: 72990-103-10 \| 11 digit: 72990-0103-10
Dosage Forms and Strengths	DefenCath catheter lock solution (CLS) is available in: 3 mL of CLS in a single-dose vial containing taurolidine 40.5 mg/3 mL (13.5 mg/mL), and heparin 3,000 USP Units/3 mL (1,000 USP Units/mL)
How Supplied	Each vial contains a sterile, preservative-free, clear aqueous-based solution for instillation in central venous catheters. Each carton contains 10 single-dose vials.

DefenCath Distributor Ordering Information

	Cardinal Health™ Specialty Pharmaceutical Distribution Customer Service: 855-855-0708	McKesson Specialty Health Customer Service: 800-482-6700
Inpatient ProcurementInpatient Hospitals Hospital Owned Entities	CARDINAL SD (IP) CIN: 5909569	Plasma and Biologics Item number: 2989606
Outpatient ProcurementDialysis Clinics Outpatient Hospitals Vascular Surgery Centers Ambulatory Surgery Centers Office-Based Laboratories Infusion Centers Specialty Pharmacies	CARDINAL SD (OP) CIN: 5921259	Plasma and Biologics Item number: 2989606 Non-Hospital Owned EntitiesSpecialty Care Distribution Item number: 5018785
Dialysis OrganizationsDialysis Centers	Metro Medical CIN: 729901	Plasma and Biologics Item number: 2989606 Specialty Care Distribution Item number: 5018785
Veterans AffairsVA Medical Centers VA Dialysis Centers	Available, Not PreferredCARDINAL SD (IP) CIN: 5909569	PreferredPlasma and Biologics Item number: 2989606

Cardinal Health™ Specialty Pharmaceutical Distribution Customer Service: 855-855-0708
Inpatient ProcurementInpatient Hospitals Hospital Owned Entities	CARDINAL SD (IP) CIN: 5909569
Outpatient ProcurementDialysis Clinics Outpatient Hospitals Vascular Surgery Centers Ambulatory Surgery Centers Office-Based Laboratories Infusion Centers Specialty Pharmacies	CARDINAL SD (OP) CIN: 5921259
Dialysis OrganizationsDialysis Centers	Metro Medical CIN: 729901
Veterans AffairsVA Medical Centers VA Dialysis Centers	Available, Not PreferredCARDINAL SD (IP) CIN: 5909569

McKesson Specialty Health Customer Service: 800-482-6700
Inpatient ProcurementInpatient Hospitals Hospital Owned Entities	Plasma and Biologics Item number: 2989606
Outpatient ProcurementDialysis Clinics Outpatient Hospitals Vascular Surgery Centers Ambulatory Surgery Centers Office-Based Laboratories Infusion Centers Specialty Pharmacies	Plasma and Biologics Item number: 2989606 Non-Hospital Owned EntitiesSpecialty Care Distribution Item number: 5018785
Dialysis OrganizationsDialysis Centers	Plasma and Biologics Item number: 2989606 Specialty Care Distribution Item number: 5018785
Veterans AffairsVA Medical Centers VA Dialysis Centers	PreferredPlasma and Biologics Item number: 2989606

DefenCath^® (taurolidine and heparin) catheter lock solution Resource Portal

Access important product information, tools, billing, and other resources

Learn best practices for health system integration, download communication templates, and access videos—and much more!

DefenCath Reimbursement Support Program

Offering support and resources for:

Reimbursement
Coverge
Billing
Ordering
Coding

Speak with a representative

Have questions about DefenCath? Open the form below to request a call with a representative.

Open form

IMPORTANT SAFETY INFORMATION (cont'd)

CONTRAINDICATIONS

DefenCath is contraindicated in patients with:

Known heparin-induced thrombocytopenia (HIT).
Known hypersensitivity to taurolidine, heparin or the citrate excipient (components of DefenCath), or pork products.

WARNINGS AND PRECAUTIONS

Heparin-Induced Thrombocytopenia (HIT): HIT was reported in patients using heparin, a component of DefenCath, as a catheter lock solution. If HIT occurs, discontinue DefenCath and institute appropriate supportive measures.
Drug Hypersensitivity: Drug hypersensitivity reactions have been reported in patients using heparin, a component of DefenCath, as a catheter lock solution. If a hypersensitivity reaction occurs, discontinue DefenCath and institute appropriate supportive measures.

ADVERSE REACTIONS

The most frequently reported adverse reactions occurring in ≥2% of patients using DefenCath as a CLS were hemodialysis catheter malfunction, hemorrhage/bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia.

To report SUSPECTED ADVERSE REACTIONS, contact CorMedix Inc at 1-844-424-6345 or FDA at 1-800-FDA-1088 or .

Indications and Usage

LIMITED POPULATION: DefenCath^® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Limitations of Use
The safety and effectiveness of DefenCath have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.

Please see the full Prescribing Information.